© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the phase I/II DART study.
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the phase I/II DART study. The study compareddalantercept plus axitinib with placebo plus axitinib for patients with advanced clear cell renal cell carcinoma.